3/23
07:42 am
abus
Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M [Seeking Alpha]
Medium
Report
Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M [Seeking Alpha]
3/23
07:40 am
abus
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/23
07:30 am
abus
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Medium
Report
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
3/7
07:03 pm
abus
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook [Yahoo! Finance]
Medium
Report
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook [Yahoo! Finance]
3/4
05:00 pm
abus
Why Moderna (MRNA) Stock Is Trading Up Today [Yahoo! Finance]
Neutral
Report
Why Moderna (MRNA) Stock Is Trading Up Today [Yahoo! Finance]
3/4
10:13 am
abus
Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement [Yahoo! Finance]
Medium
Report
Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement [Yahoo! Finance]
3/4
09:22 am
abus
Moderna gains as Arbutus/ Genevant settlement removes major financial risk [Seeking Alpha]
Medium
Report
Moderna gains as Arbutus/ Genevant settlement removes major financial risk [Seeking Alpha]
3/4
09:21 am
abus
Moderna shares jump as settlement removes major legal overhang [Yahoo! Finance]
Low
Report
Moderna shares jump as settlement removes major legal overhang [Yahoo! Finance]
3/3
04:15 pm
abus
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
High
Report
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
2/3
08:00 am
abus
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]
Medium
Report
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]
1/23
05:06 am
abus
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.